EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board ("**Board**") of directors (the "**Directors**" and each a "**Director**") of EuroEyes International Eye Clinic Limited (the "**Company**" and its subsidiaries, collectively, the "**Group**") is pleased to announce that with effect from 3 August 2026, Mr. Rens Laurentius Michaël Schoenmakers ("**Mr. Schoenmakers**"), aged 60, has been appointed as an executive Director (the "**Appointment**").

Mr. Schoenmakers has over 20 years of experience as a chief executive officer and managing director in the medical devices, medtech and healthcare sectors across Europe, North America and Asia. Following the Group's acquisition of FYEO Europe B.V. ("**FYEO**"), Mr. Schoenmakers, who previously served as its Chief Executive Officer, was appointed as the General Manager Europe of the Group in July 2026 and will be responsible for the Group's European markets. Additionally, he has served as the Chief Executive Officer and an executive director of EuroEyes Netherlands Holding B.V., a subsidiary of the Company since July 2026.

From April 2019 to July 2026, Mr. Schoenmakers served as Chief Executive Officer of FYEO in the Netherlands, the leading brand for refractive surgery in the Netherlands. Prior to that, he served as Chief Executive Officer of Welzorg Nederland B.V. from March 2014 to September 2017 (also based in the Netherlands) and the Managing Director and Senior Vice President of Handicare Group AB (the shares of which were formerly listed on Nasdaq Stockholm) across Europe, North America and Asia from May 2002 to June 2012.

Mr. Schoenmakers also previously held senior management positions, including as (i) Managing Director of Smartmission Benelux B.V. from June 2000 to August 2001; (ii) Managing Director of The Netherlands of HillRom (previously known as Hill-Rom Holdings, Inc. and whose shares of which were formerly listed on the New York Stock Exchange) from May 1997 to May 2000; (iii) Commercial Director of Vihome Group B.V. from June 1992 to April 1997 in the Netherlands; and (iv) Commercial Manager of Troy Special Products B.V. from September 1990 to May 1992 in the Netherlands.

Mr. Schoenmakers has obtained various post-graduate diplomas, including (i) the Leadership Trail in South Africa from the Foundation for Natural Leadership in April 2018; (ii) for Corporate Strategy at MIT Sloan School of Management in Boston, USA in 2008; (iii) for Strategic Issues in Mergers and Acquisitions at INSEAD, Fontainebleau, France in 2007; (iv) for Interpersonal Skills for Senior Managers at the London Business School, UK in 1999; and (v) for Financial Management at the Stanford Business School, Palo Alto, USA in July 1998. He graduated from Nyenrode University in the Netherlands with a Bachelor of Business Administration degree in July 1991.

A service agreement has been entered into between Mr. Schoenmakers and the Company pursuant to which he has been appointed for a term of two (2) years as an executive Director. Mr. Schoenmakers will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the requirements of the articles of association of the Company. Pursuant to the service agreement, Mr. Schoenmakers is entitled to a director's fee of EUR3,400 per month. In addition, he is entitled to a salary of EUR36,600 per month for his senior management roles within the Group. His total remuneration package was determined by the Board and the remuneration committee of the Board, with reference to his duties and responsibilities with the Group, the Group's remuneration policy and the prevailing market conditions and practice. Furthermore, Mr. Schoenmakers is entitled to a discretionary bonus and other benefits, which will be determined by the Group with reference to its operating results and his individual performance.

Save as disclosed above, as at the date of this announcement, Mr. Schoenmakers (i) did not hold any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas for the last three years; (ii) does not have any other major appointments and professional qualifications; (iii) does not have any interests in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (iv) does not hold any other position with the Company or other members of the Group; and (v) does not have any relationships with any directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company.

Save as disclosed herein, there is no other information relating to the Appointment that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matters which need to be brought to the attention of the shareholders of the Company as at the date of this announcement.

The Board would like to extend its warm welcome to Mr. Schoenmakers.

By order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Mr. Jannik Jonas Slot Jørgensen, Professor Dan Zoltan Reinstein, Mr. Marcus Huascar Bracklo and Mr. Rens Laurentius Michaël Schoenmakers as executive Directors; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.